(CLGN) – Company Press Releases
-
COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
-
COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
-
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
-
CollPlant Issues Letter to Shareholders
-
CollPlant's CEO to Present at the Octane Aesthetic Tech Forum Conference, in Newport Beach, California
-
CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants
-
CollPlant Biotechnologies Announces Third Quarter Financial Results for 2023
-
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
-
CollPlant Biotechnologies Announces Patent Granted in U.S. for Photocurable Dermal Filler
-
CollPlant Biotechnologies Joins the United Nations Global Compact, The World's Largest Corporate Sustainability Initiative
-
CollPlant to Present at the H.C. Wainwright Annual Growth Conference
-
CollPlant Biotechnologies Announces Second Quarter Financial Results For 2023 with Revenues of $10.2 Million
-
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2022 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
-
CollPlant Achieves Milestone and To Receive $10 Million From AbbVie in Accordance with its Regenerative Dermal Filler Product Collaboration Agreement
-
CollPlant Biotechnologies Announces First Quarter Financial Results For 2023 and Provides Corporate Update
-
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
-
Stratasys and CollPlant Unite Technologies to Transform Healthcare with Industrial-Scale Bioprinting of Tissues and Organs
-
Collplant Biotechnologies Announces Full-Year Financial Results For 2022 and Provides Corporate Update
-
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2022 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
-
CollPlant Issues Letter to Shareholders
-
CollPlant Announces Successful Pre-Clinical Results in 3D Bioprinted Regenerative Breast Implants Porcine Study and Full Achievement of Objectives
-
CollPlant Enriches Portfolio of rhCollagen-Based Bioinks with Launch of Collink.3DTM 50L in Powder Form
-
CollPlant Biotechnologies Provides Business Updates and Third Quarter 2022 Financial Results
-
CollPlant, Tel Aviv University and Sheba Medical Center Join Forces to Co-Develop rhCollagen-Based 3D Bioprinted Human Intestine Model for Drug Discovery and Personalized Treatment of Ulcerative Colit
-
CollPlant Expands rhCollagen-Based Bioink Platform with Launch of Collink.3D™ 90
-
CollPlant to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 17
-
CollPlant to present at the Dawson James Small Cap Growth Conference on October 12
-
CollPlant to Present at the International Conference on Biofabrication 2022 in Tuscany, Italy
-
CollPlant Biotechnologies to Participate in September Investor Conferences
-
CollPlant Biotechnologies Provides Business Updates and Second Quarter 2022 Financial Results
-
CollPlant to Present and Exhibit at TERMIS Annual Conference in Toronto, Canada
-
CollPlant Advances its 3D Bioprinted Regenerative Breast Implants into Porcine Study
-
CollPlant Biotechnologies Provides Business Updates and First Quarter 2022 Financial Results
-
Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman
-
Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman
-
CollPlant CEO Yehiel Tal to Moderate ISBF's virtual event on Biofabrication of Microphysiological Systems for Drug Discovery and Screening
-
CollPlant To Present at the Aesthetics Innovation Summit 2022
-
CollPlant Biotechnologies Provides Business Updates and Fiscal Year 2021 Financial Results
-
CELLINK and CollPlant Enter a Collaboration Agreement to Explore Future Large-Scale Production of CollPlant's Regenerative Breast Implants using CELLINK's Bioprinting technologies
-
RION Appoints Alisa Lask as Chief Commercial Officer
-
CollPlant Issues Letter to Shareholders
-
CollPlant Announces Publication Highlighting its rhCollagen-based Photocurable Dermal Filler in the Plastic and Reconstructive Surgery Journal
-
CollPlant Biotechnologies Provides Business Updates and Third Quarter 2021 Financial Results
-
CollPlant Announces Commercial Launch of BioInk Platform with Collink.3D™ for Use in 3D Bioprinting of Human Tissues, Scaffolds and Organs
-
CollPlant to Present at Dawson James Small Cap Growth Conference on October 21st
-
CollPlant's rhCollagen BioInk Used by Technion Researchers to Develop 3D Bioprinted Vascularized Tissue Constructs
-
CollPlant to Present at Fall Harvest - Best Ideas from the Buy-Side on October 5, 2021
-
CollPlant CEO Yehiel Tal to Discuss Emerging Uses of rhCollagen in Aesthetic and Regenerative Medicine at NANO.IL.2021 Conference
-
CollPlant CEO Yehiel Tal elected to the Board of Directors of the International Society for Biofabrication (ISBF)
-
CollPlant To Present at the H.C. Wainwright Annual Global Investment Conference in September
Back to CLGN Stock Lookup
